A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/16/2006	US20060258672 Multicyclic compounds and methods of their use
11/16/2006	US20060258671 Phenylpyridylpiperazine compounds
11/16/2006	US20060258670 New phenylpyridylpiperazine compounds
11/16/2006	US20060258669 Therapeutic agents useful for treating pain
11/16/2006	US20060258668 Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders
11/16/2006	US20060258667 Method for improving respiratory function and inhibiting muscular degeneration
11/16/2006	US20060258666 c-fms kinase inhibitors
11/16/2006	US20060258665 Bridged ring NK1 antagonists
11/16/2006	US20060258664 Method for the production of riboflavin of modification b/c in granular form
11/16/2006	US20060258663 Cyclic G-2AllylProline in treatment of Parkinson's disease
11/16/2006	US20060258662 Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
11/16/2006	US20060258661 N-(pyridin-2-ylmethyl)-4-methyl-3-oxo-4-aza-5 alpha -androst-1-en-17 beta -acetamide; enhancement of weakened muscle tone; osteoporosis, bone disorders; ; periodontal disease, frailty, aging skin, male hypogonadism, postmenopausal symptoms, inflammatory arthritis, cachexia, Alzheimer's disease
11/16/2006	US20060258660 Stabilization of hypoxia inducible factor (HIF) alpha
11/16/2006	US20060258659 Heterocyclic compounds and their uses as therapeutic agents
11/16/2006	US20060258658 Triazole compounds useful as protein kinase inhibitors
11/16/2006	US20060258657 Apoptosis promoters
11/16/2006	US20060258656 Compositions and methods for treating cancer
11/16/2006	US20060258655 Crystalline forms of linezolid intermediate
11/16/2006	US20060258654 Pyridinylmorpholine derivatives
11/16/2006	US20060258653 Derivatives of sulphonamides, their preparation and use as medicaments
11/16/2006	US20060258652 Beta-blockers having antioxidant and no-donor activity
11/16/2006	US20060258651 Use of heterocyclic compounds as scce inhibitors
11/16/2006	US20060258650 Phenothiazine enantiomers as agents for the prevention of bone loss
11/16/2006	US20060258648 9-Azabicyclo'3.3.1 inon-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors
11/16/2006	US20060258647 Treatment of maladaptive substance use with cholecystokinin (CCK) antagonists
11/16/2006	US20060258646 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
11/16/2006	US20060258645 Pyrrolobenzodiazepines and heterocyclic carboxamide derivatives as follicle stimulating hormone receptor (FSH-R) antagonists
11/16/2006	US20060258644 Pyrrolobenzodiazepines and heteroaryl, aryl and cycloalkylamino ketone derivatives as follicle stimulating hormone receptor (FSH-R) antagonists
11/16/2006	US20060258643 Gabaergic agents to treat memory deficits
11/16/2006	US20060258642 Confining solid tumors; administering a tyrosine kinase inhibitor as antitumor agents; 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline
11/16/2006	US20060258641 Methods and compositions of novel triazine compounds
11/16/2006	US20060258640 Use of Flibanserin in the treatment of chronic pain
11/16/2006	US20060258639 Therapeutic combinations for the treatment or prevention of psychotic disorders
11/16/2006	US20060258638 Succinoylamino lactams as inhibitors of A-beta protein production
11/16/2006	US20060258637 Fused polycyclic compounds
11/16/2006	US20060258636 comprising from 10 to 16% of acetonitrile; for preparing the antibiotic cefuroxime sodium salt; treating gramnegative bacteria infections
11/16/2006	US20060258635 Use of a porphyrin compound for the treatment of skin fungi
11/16/2006	US20060258634 for the treatment and/or prevention of cancer; especially ovarian cancer; antimetastatic agent
11/16/2006	US20060258633 Amorphous tegaserod maleate
11/16/2006	US20060258632 Methods and agents for treating cardiovascular diseases
11/16/2006	US20060258631 Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same
11/16/2006	US20060258630 Method for the prevention and treatment of uveitis
11/16/2006	US20060258629 Photodynamic therapy for ocular neovascularization
11/16/2006	US20060258628 Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
11/16/2006	US20060258627 Enzyme inhibitor for treating HIV infections in mammals; viricides; patient is suffering from a multi-drug resistant HIV infection; Aids therapy
11/16/2006	US20060258626 Use of inositol-tripyrophosphate in treating tumors and diseases
11/16/2006	US20060258625 Process for the preparation of biphosphonic derivatives
11/16/2006	US20060258624 Composition and method for reducing the appearance of cellulite
11/16/2006	US20060258623 Absorption of fat-soluble nutrients
11/16/2006	US20060258622 Methods of and compositions for reducing neuronal cell death
11/16/2006	US20060258621 Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv
11/16/2006	US20060258620 anticancer agents; angiogenesis inhibitors; fatty acid synthase inhibitors
11/16/2006	US20060258619 Compounds such as 4-[5-(4-Bromophenyl)-3-trimethylsilanyl-pyrazol-1-yl]-benzenesulfonamide or 2-(4-Bromophenyl)-2-(4-methanesulfonylphenyl)-5-trifluoromethyl-2H-[1,2]azasilole; relieving an inflammatory condition
11/16/2006	US20060258618 Anti-inflammatory substituted phenols and elastomeric compositions for oral delivery of drugs
11/16/2006	US20060258617 Drug delivery to the back of the eye
11/16/2006	US20060258616 Natural semi-synthetic and synthetic lipid derivatives of ceramide and sphingosine groups, drugs and the medical use thereof in the form of therapeutic agents in particular for dermatology
11/16/2006	US20060258615 Administering to a mammal P1,P4-di(uridine 5'-)tetraphosphate, tetralithium salt; or P1,P4-di(uridine 5'-)tetraphosphate, tetrapotassium salt; in a pharmaceutically acceptable carrier to treat dry eye or retinal detachment
11/16/2006	US20060258614 Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
11/16/2006	US20060258613 6-Oxyamino-7-deazapurin-9-yl-2-substituted ribofuranose derivatives, e.g., 1-(6-hydroxylamino-7-ethenyl-7-deazapurin-9-yl)-2-methyl- beta -D-ribofuranose; treating viral infections mediated by a virus in the flaviviridae family
11/16/2006	US20060258612 CFTR channel modulators
11/16/2006	US20060258602 Site-specific gene conversion promoter and gene therapeutic
11/16/2006	US20060258601 Formulation for inwardly transferring nucleic acids into eucaryotic cells
11/16/2006	US20060258600 Ether linked macrolides useful for the treatment of microbial infections
11/16/2006	US20060258599 Methods and composition for the treatment of cystic fibrosis and related illnesses
11/16/2006	US20060258580 Such as N-acyl/myristoyl-gamma-glucose-diaminopimelic acid dipeptides; for activation of nuclear factor kappa beta; for treatment of inflammatory diseases such as Crohn's disease and asthma; drug screening
11/16/2006	US20060258578 Pharmaceutical composition
11/16/2006	US20060258571 Antibacterial ester macrocycles
11/16/2006	US20060258561 Novel NPH insulin preparations
11/16/2006	US20060258537 etherification of cyclodextrin using hydroxy(C2-C6 alkylene)-sulfonic acid sodium salt and hydroxyalkyl compound; can be used to solubilize compounds with insufficient water solubility; osmotic agents, agents used to mask the taste of problematic drugs
11/16/2006	US20060257987 Ppar modulators
11/16/2006	US20060257981 culturing a microorganism belonging to the species Dactylosporangium, in a nutrient medium and isolating tiacumicin B; antibiotics used for prophylaxis and therapy of bacterial infections
11/16/2006	US20060257977 Slowly digestible starch
11/16/2006	US20060257965 Extracellular matrix signalling molecules
11/16/2006	US20060257928 ANGE gene in atopy
11/16/2006	US20060257911 Of given nucleotide sequence; diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders
11/16/2006	US20060257882 Novel polynuceotides and polypeptides encoded thereby
11/16/2006	US20060257872 Cell lines and host nucleic acid sequences related to infectious disease
11/16/2006	US20060257843 Kappa-PVIIA-related conotoxins as organ protectants
11/16/2006	US20060257540 safflower seed extract prepared by washing a defatted safflower seed with water to obtain a washed product, separating the washed product from a resulting washing liquid, and extracting the washed product with an organic solvent; for reducing risk of developing atherosclerosis
11/16/2006	US20060257510 Pharmaceutical compositions for the treatment of ulcerations
11/16/2006	US20060257508 Pharmaceutical compositions for alleviating excess levels of sugar in diabetic patients
11/16/2006	US20060257505 Bioavailability enhancing activity of carum carvi extracts and fractions thereof
11/16/2006	US20060257503 Nutritional supplement and method for providing supplemental nutrition to an athlete
11/16/2006	US20060257502 A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders
11/16/2006	US20060257501 Composition and method for the therapeutic modulation of matrix metalloproteinase
11/16/2006	US20060257500 TRPC6 involved in glomerulonephritis
11/16/2006	US20060257499 Vaginal rinse with enhanced bacteriocidal activity
11/16/2006	US20060257494 Coated tablets
11/16/2006	US20060257493 Nanoparticulate delivery systems for treating multi-drug resistance
11/16/2006	US20060257491 Dry powder composition comprising co-jet milled particles for pulmonary inhalation
11/16/2006	US20060257490 Formulation based on phospholipids
11/16/2006	US20060257489 Fine particles, method and device for preparation thereof, and agent for parenteral injection and method for production thereof
11/16/2006	US20060257487 Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
11/16/2006	US20060257484 Combination of tramadol and substances that comprise gabapentin
11/16/2006	US20060257483 Controlled release bupropion dosage forms
11/16/2006	US20060257482 Modified release, multiple unit drug delivery systems
11/16/2006	US20060257481 Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
11/16/2006	US20060257480 Pharmaceutical formulations of amyloid inhibiting compounds
11/16/2006	US20060257476 Tablet formulation
11/16/2006	US20060257475 Stable Sertraline Hydrochloride Formulation and Method

1 ... 4005 4006 4007 4008 4009 4010 4011 4012 4013 4014 4015 4016 4017 4018 4019 4020 4021 4022 4023 4024 4025 ... 7860